Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Fresenius SE & Co KGaA stock

FRE.DE
DE0005785604
578560

Price

37.16
Today +/-
+0.03
Today %
+0.08 %

Fresenius SE & Co KGaA stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Fresenius SE & Co KGaA stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Fresenius SE & Co KGaA stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Fresenius SE & Co KGaA stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Fresenius SE & Co KGaA's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Fresenius SE & Co KGaA Stock Price History

DateFresenius SE & Co KGaA Price
1/29/202537.16 undefined
1/28/202537.13 undefined
1/27/202536.92 undefined
1/24/202536.72 undefined
1/23/202536.80 undefined
1/22/202535.91 undefined
1/21/202536.21 undefined
1/20/202536.38 undefined
1/17/202536.30 undefined
1/16/202535.60 undefined
1/15/202535.39 undefined
1/14/202534.81 undefined
1/13/202534.54 undefined
1/10/202535.08 undefined
1/9/202535.07 undefined
1/8/202534.52 undefined
1/7/202534.17 undefined
1/6/202534.22 undefined
1/3/202533.49 undefined
1/2/202533.49 undefined

Fresenius SE & Co KGaA Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fresenius SE & Co KGaA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fresenius SE & Co KGaA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fresenius SE & Co KGaA’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fresenius SE & Co KGaA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fresenius SE & Co KGaA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fresenius SE & Co KGaA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fresenius SE & Co KGaA’s growth potential.

Fresenius SE & Co KGaA Revenue, EBIT and net profit per share

DateFresenius SE & Co KGaA RevenueFresenius SE & Co KGaA EBITFresenius SE & Co KGaA Net Income
2030e29.37 B undefined0 undefined0 undefined
2029e28.46 B undefined0 undefined0 undefined
2028e25.95 B undefined3.33 B undefined2.52 B undefined
2027e25.2 B undefined3.28 B undefined2.45 B undefined
2026e24.03 B undefined2.87 B undefined2.15 B undefined
2025e22.94 B undefined2.62 B undefined1.9 B undefined
2024e21.83 B undefined2.36 B undefined1.65 B undefined
202322.3 B undefined1.2 B undefined-594 M undefined
202221.53 B undefined1.84 B undefined1.37 B undefined
202137.52 B undefined4.18 B undefined1.82 B undefined
202036.28 B undefined4.36 B undefined1.71 B undefined
201935.41 B undefined4.63 B undefined1.88 B undefined
201833.53 B undefined4.45 B undefined2.03 B undefined
201733.89 B undefined4.56 B undefined1.81 B undefined
201629.47 B undefined4.33 B undefined1.56 B undefined
201528 B undefined3.94 B undefined1.39 B undefined
201423.46 B undefined3.12 B undefined1.07 B undefined
201320.55 B undefined2.99 B undefined988 M undefined
201219.51 B undefined2.99 B undefined930 M undefined
201116.52 B undefined2.56 B undefined690 M undefined
201015.97 B undefined2.42 B undefined619 M undefined
200914.17 B undefined2.05 B undefined475 M undefined
200812.35 B undefined1.76 B undefined528 M undefined
200711.39 B undefined1.65 B undefined422 M undefined
200610.78 B undefined1.44 B undefined330 M undefined
20057.89 B undefined969 M undefined222 M undefined
20047.27 B undefined845 M undefined168 M undefined

Fresenius SE & Co KGaA Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
1.933.954.565.126.337.587.517.067.277.8910.7811.3912.3514.1715.9716.5219.5120.5523.462829.4733.8933.5335.4136.2837.5221.5322.321.8322.9424.0325.225.9528.4629.37
-105.1915.3712.4223.4819.78-0.92-5.902.938.5036.605.718.4514.6712.763.4418.075.3214.1819.345.2714.98-1.055.602.453.43-42.613.56-2.125.094.764.872.989.673.20
64.6266.9968.2967.3666.8767.3932.4532.2232.6834.0931.8932.5231.9232.7933.3334.1333.3732.1330.1531.8732.2830.9629.3329.2228.4427.4825.0922.6823.1722.0521.0520.0719.4917.7717.22
1.242.653.113.454.235.112.442.282.382.693.443.73.944.645.325.646.516.67.078.929.5110.499.8310.3510.3210.315.45.060000000
0.060.060.10.110.120.080.130.120.170.220.330.420.530.480.620.690.930.991.071.391.561.812.031.881.711.821.37-0.591.651.92.152.452.5200
--74.583.8814.02-32.7963.41-14.1846.0932.1448.6527.8825.12-10.0430.3211.4734.786.248.3029.5312.5516.2811.74-7.10-9.356.50-24.53-143.29-378.1115.1312.9314.152.69--
-----------------------------------
-----------------------------------
305305369369369374378378379380464469477485488493524540544.3548.16550.08557.51557.3557.42557.74558.16561.26563.240000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Fresenius SE & Co KGaA Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Fresenius SE & Co KGaA is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
                                                     
0.130.130.190.120.190.20.160.130.140.250.260.360.370.430.780.640.920.891.281.251.771.462.591.541.720.930.57
0.660.880.8111.121.371.31.421.531.872.092.162.482.512.943.233.723.544.294.685.316.296.637.887.417.537.45
0.10.160.260.290.40.430.020.020.020.020.010.010.320.140.130.560.50.620.930.880.740.921.141.091.281.781.67
0.290.330.410.490.570.640.660.640.620.730.760.881.131.241.411.721.842.022.332.863.193.253.223.633.954.224.83
0000000.610.540.450.670.730.60.520.820.850.990.710.540.730.770.740.681.221.121.4233.75
1.181.511.671.92.272.632.742.742.763.533.854.014.825.136.117.157.77.69.5710.4311.7412.614.7915.2615.7717.4618.28
0.761.031.091.31.51.851.81.721.72.362.722.973.423.563.964.214.925.086.787.438.149.5610.3717.2717.618.5818.84
67888297149145000012141066924878773974803392561900000
000000000000821121018682996148746055572322013200
0.050.060.120.150.160.160.580.50.480.540.570.571.371.291.230.981.51.411.641.731.763.173.133.873.743.834.4
1.71.841.982.022.22.53.412.982.914.687.127.0910.4710.4511.5712.6715.1114.9219.9821.6522.925.2925.7127.7426.628.9431.44
0.010.030.030.250.210.290.390.40.350.490.760.670.550.530.630.440.7431.161.171.431.941.982.652.83.143.45
2.593.043.293.814.24.946.175.65.438.0611.1811.321616.0217.7319.1723.125.2629.6132.834.9540.5341.9151.7450.8754.558.14
3.774.554.965.716.477.578.928.358.1911.5915.0215.3320.8321.1523.8326.3230.832.8639.1743.2346.753.1356.767.0166.6571.9676.42
                                                     
4651515151105105105105130132155161161162163178180542546547555556557557558563
00000000000000000000000004.034.32
0.350.40.40.650.630.541.351.421.542.613.013.364.094.484.985.777.768.539.0510.2711.5413.515.1916.4117.5318.8919.45
0.290.390.850.961.021.630.150.01-0.040.10.06-0.09-0.09-0.130.10.040.03-0.32-0.070.330.57-0.4-0.33-0.19-1.14-0.450.41
000000000000000000000000000
0.680.851.31.671.712.281.611.541.62.843.23.434.174.515.245.977.978.389.5211.1512.6613.6615.4116.7816.9523.0224.74
0.160.220.230.320.340.340.30.270.270.350.460.490.60.60.690.810.960.891.051.291.321.691.821.911.822.042.07
00000000000000002.22.292.92.873.032.913.31.060.921.151.49
0.230.270.330.920.540.481.341.231.21.71.982.522.312.383.493.11.350.91.352.242.683.053.065.426.827.17.06
0.070.020.0500.030.020.560.130.390.220.330.360.730.290.610.170.212.380.2300002.480.252.840.86
1.350.160.480.310.450.670.050.50.190.230.270.120.540.270.981.911.021.081.451.262.063.025.093.033.431.932.18
1.810.671.091.541.361.512.252.132.062.53.053.484.173.545.765.995.747.536.987.679.0810.6713.2813.8813.2215.0613.66
01.520.971.331.371.351.61.421.222.064.334.327.517.747.187.779.699.4813.9313.6112.8416.1414.0421.7522.2422.3824.73
00000.010.010.180.230.250.30.360.330.60.560.650.570.870.760.930.880.941.111.281.421.391.521.67
0.890.971.030.830.931.271.521.361.321.611.491.11.311.41.021.091.141.492.262.632.993.53.13.373.773.714.14
0.892.4822.162.312.633.33.012.793.976.185.759.429.718.859.4411.7111.7317.1117.1216.7720.7518.4226.5427.4127.6130.54
2.73.153.093.73.664.145.555.134.846.469.239.2313.5913.2414.6115.4317.4519.2624.124.7825.8531.4131.740.4340.6242.6744.2
3.3844.395.375.376.427.156.676.449.3112.4312.6517.7617.7519.8521.425.4227.6533.6235.9338.5145.0747.1157.257.5765.768.94
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Fresenius SE & Co KGaA provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Fresenius SE & Co KGaA's financial health and stability.

Assets

Fresenius SE & Co KGaA's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Fresenius SE & Co KGaA must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Fresenius SE & Co KGaA after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Fresenius SE & Co KGaA's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.150.20.270.180.130.120.170.220.330.420.530.971.21.331.731.71.812.342.683.033.713.032.822.822.120.24
0.30.340.390.470.340.330.320.320.410.430.520.620.660.670.790.90.961.121.221.441.52.412.722.672.971.48
0000548025107627128-4481-16-363-613-230100714384-115-17
-0.23-0.17-0.2-0.15-0.09-0.070.13-0.03-0.080.04-0.43-0.030.05-0.39-0.07-0.25-0.28-0.03-0.31-0.18-0.69-1.181.03-0.53-0.660.4
0.080.020.010.010.260.320.210.250.330.390.3300-00.01-0.010.01-0.030-0.12-0.88-0.07-0.060.04-0.122.32
0000273244228208393388410554534474580563567575562566519733627517610403
00000.140.170.180.360.350.320.360.390.50.520.660.650.780.860.891.190.920.770.770.750.850.36
0.280.40.460.510.70.780.850.781.061.31.081.561.921.692.452.342.563.353.593.943.744.266.555.084.24.42
0000-377-339-308-353-595-711-767-687-764-783-985-1,088-1,366-1,511-1,641-1,823-2,149-2,459-2,406-2,047-1,917-1,134
-674-354-763-704-433-393-376-1,937-3,796-1,064-3,698-899-1,246-2,072-3,265-3,619-3,326-1,516-2,101-7,570-1,464-4,856-3,011-2,817-2,607-3,187
-674-354-763-704-56-54-68-1,584-3,201-353-2,931-212-482-1,289-2,280-2,531-1,960-5-460-5,747685-2,397-605-770-690-2,053
00000000000000000000000000
-0.08-0.090.15-0.160.22-0.03-0.480.62.460.152.69-0.16-0.370.560.81.891.51-1.25-0.434.62-0.130.64-1.32-0.4-0.780.76
000.610.010001.010.080.06-0.130.060.120.11.15-0.230.130.170.080.020.06-0.55-0.350.040.020
0.45-0.110.360.19-0.26-0.41-0.461.262.76-0.122.62-0.61-0.350.241.071.31.04-1.98-0.973.87-1.27-0.48-3.12-1.45-1.6-1.38
57629-336437-385-269140-219400-121303-234221-55-437142-5-263116157-290381-980-60145-1,589
-46-52-63-98-101-114-122-132-171-205-245-275-329-365-446-491-582-639-738-924-904-952-468-491-890-550
0.06-0.070.07-0-0.02-0.040.020.110.010.10.010.050.35-0.130.25-0.020.31-0.130.540.061.07-1.060.180.93-0.02-0.19
2843974635123204375434274635923138771,1579061,4681,2491,1941,8381,9442,1141,5931,8044,1433,0312,2813,286
00000000000000000000000000

Fresenius SE & Co KGaA stock margins

The Fresenius SE & Co KGaA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fresenius SE & Co KGaA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fresenius SE & Co KGaA.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fresenius SE & Co KGaA's sales revenue. A higher gross margin percentage indicates that the Fresenius SE & Co KGaA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fresenius SE & Co KGaA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fresenius SE & Co KGaA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fresenius SE & Co KGaA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fresenius SE & Co KGaA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fresenius SE & Co KGaA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fresenius SE & Co KGaA Margin History

Fresenius SE & Co KGaA Gross marginFresenius SE & Co KGaA Profit marginFresenius SE & Co KGaA EBIT marginFresenius SE & Co KGaA Profit margin
2030e22.68 %0 %0 %
2029e22.68 %0 %0 %
2028e22.68 %12.84 %9.71 %
2027e22.68 %13.01 %9.73 %
2026e22.68 %11.92 %8.94 %
2025e22.68 %11.4 %8.3 %
2024e22.68 %10.83 %7.57 %
202322.68 %5.36 %-2.66 %
202225.09 %8.53 %6.37 %
202127.48 %11.14 %4.85 %
202028.44 %12.02 %4.71 %
201929.22 %13.07 %5.32 %
201829.33 %13.27 %6.05 %
201730.96 %13.47 %5.35 %
201632.28 %14.69 %5.29 %
201531.87 %14.08 %4.95 %
201430.15 %13.3 %4.56 %
201332.13 %14.55 %4.81 %
201233.37 %15.32 %4.77 %
201134.13 %15.51 %4.18 %
201033.33 %15.17 %3.88 %
200932.79 %14.47 %3.35 %
200831.92 %14.25 %4.27 %
200732.52 %14.46 %3.7 %
200631.89 %13.39 %3.06 %
200534.09 %12.28 %2.81 %
200432.68 %11.62 %2.31 %

Fresenius SE & Co KGaA Stock Sales Revenue, EBIT, Earnings per Share

The Fresenius SE & Co KGaA earnings per share therefore indicates how much revenue Fresenius SE & Co KGaA has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fresenius SE & Co KGaA earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fresenius SE & Co KGaA's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fresenius SE & Co KGaA’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fresenius SE & Co KGaA's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fresenius SE & Co KGaA Revenue, EBIT and net profit per share

DateFresenius SE & Co KGaA Sales per ShareFresenius SE & Co KGaA EBIT per shareFresenius SE & Co KGaA Earnings per Share
2030e52.14 undefined0 undefined0 undefined
2029e50.53 undefined0 undefined0 undefined
2028e46.07 undefined0 undefined4.47 undefined
2027e44.74 undefined0 undefined4.35 undefined
2026e42.66 undefined0 undefined3.81 undefined
2025e40.72 undefined0 undefined3.38 undefined
2024e38.75 undefined0 undefined2.93 undefined
202339.59 undefined2.12 undefined-1.05 undefined
202238.36 undefined3.27 undefined2.44 undefined
202167.22 undefined7.49 undefined3.26 undefined
202065.04 undefined7.82 undefined3.06 undefined
201963.52 undefined8.3 undefined3.38 undefined
201860.16 undefined7.98 undefined3.64 undefined
201760.78 undefined8.18 undefined3.25 undefined
201653.58 undefined7.87 undefined2.84 undefined
201551.07 undefined7.19 undefined2.53 undefined
201443.1 undefined5.73 undefined1.97 undefined
201338.05 undefined5.54 undefined1.83 undefined
201237.23 undefined5.7 undefined1.77 undefined
201133.51 undefined5.2 undefined1.4 undefined
201032.73 undefined4.97 undefined1.27 undefined
200929.21 undefined4.23 undefined0.98 undefined
200825.9 undefined3.69 undefined1.11 undefined
200724.29 undefined3.51 undefined0.9 undefined
200623.22 undefined3.11 undefined0.71 undefined
200520.76 undefined2.55 undefined0.58 undefined
200419.18 undefined2.23 undefined0.44 undefined

Fresenius SE & Co KGaA business model

Fresenius SE is a German pharmaceutical and medical technology company, which was founded in 1912 by Eduard Fresenius. The company's history is marked by continuous growth and numerous acquisitions, which have shaped the current corporate structure. Fresenius operates in four different divisions: Fresenius Medical Care is a global leader in dialysis treatment and offers products as well as services related to dialysis. Fresenius Kabi specializes in the production of medications and medical devices for infusion and nutrition therapy. Fresenius Helios is one of the largest providers of hospital treatments with over 110 clinics and operates facilities in Germany, Spain, and Latin America. Fresenius Vamed offers services related to the management and planning of healthcare facilities and operates worldwide in over 85 countries. The business model of Fresenius SE is based on the development and production of innovative medical products, as well as the provision of services in the healthcare sector. The company relies on high-quality products and intensive research and development. A key factor for success is focusing on the needs of customers and patients to ensure the best possible care. One of the most well-known products of Fresenius SE are the Fresenius concentrates for dialysis treatment. These enable effective and gentle blood cleansing, thereby improving the quality of life for dialysis patients. Another example of innovative products are the 3-in-1 infusion systems by Fresenius Kabi. These combine the administration of fluids, medications, and nutrition into one system, offering significantly higher efficiency in patient care. Fresenius Helios focuses on patient-centered care and offers a wide range of medical services. The company operates both acute care clinics and long-term care facilities and utilizes state-of-the-art technologies to improve diagnosis and treatment. Fresenius Vamed provides its customers with services such as facility management, planning, and project management for healthcare facilities, as well as operational consulting. The comprehensive expertise in all areas of the healthcare industry ensures high quality in the implementation of construction projects and renovations. In summary, Fresenius SE is an internationally active company specializing in the provision of high-quality products and services in the healthcare sector. The company focuses on patient-centered care and the continuous development of innovative products and technologies. Fresenius SE & Co KGaA is one of the most popular companies on Eulerpool.com.

Fresenius SE & Co KGaA SWOT Analysis

Strengths

Fresenius SE possesses several key strengths:

  • Established presence and reputation in the healthcare industry
  • Diversified product portfolio spanning pharmaceuticals, medical devices, and services
  • Strong financial performance and stability
  • Global operations and strong market position
  • Strong research and development capabilities

Weaknesses

Despite its overall strength, Fresenius SE also faces certain weaknesses:

  • Dependency on third-party suppliers for key components
  • Regulatory challenges in different markets
  • Relatively high debt levels
  • Competitive pressures in the healthcare industry

Opportunities

Fresenius SE can capitalize on the following opportunities:

  • Increasing demand for healthcare products and services, driven by aging population and emerging markets
  • Expanding its product portfolio through strategic acquisitions and partnerships
  • Advancements in technology opening up new possibilities for product innovation
  • Expanding into underserved or untapped markets

Threats

Fresenius SE must be cautious of the following potential threats:

  • Intense competition from global and local players
  • Changing regulatory frameworks and compliance requirements
  • Volatility in raw material prices
  • Economic downturns impacting healthcare spending
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Fresenius SE & Co KGaA Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Fresenius SE & Co KGaA historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Fresenius SE & Co KGaA shares outstanding

The number of shares was Fresenius SE & Co KGaA in 2024 — This indicates how many shares 563.237 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fresenius SE & Co KGaA earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fresenius SE & Co KGaA's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fresenius SE & Co KGaA’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fresenius SE & Co KGaA's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fresenius SE & Co KGaA stock splits

In Fresenius SE & Co KGaA's history, there have been no stock splits.

Fresenius SE & Co KGaA dividend history and estimates

In 2024, Fresenius SE & Co KGaA paid a dividend amounting to 0.93 EUR. Dividend means that Fresenius SE & Co KGaA distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Fresenius SE & Co KGaA provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Fresenius SE & Co KGaA’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Fresenius SE & Co KGaA's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Fresenius SE & Co KGaA Dividend History

DateFresenius SE & Co KGaA Dividend
2030e0.96 undefined
2029e0.96 undefined
2028e0.96 undefined
2027e0.96 undefined
2026e0.96 undefined
2025e0.97 undefined
2024e0.96 undefined
20230.92 undefined
20220.26 undefined
20211.76 undefined
20200.84 undefined
20190.8 undefined
20180.75 undefined
20170.62 undefined
20160.55 undefined
20150.44 undefined
20140.42 undefined
20130.37 undefined
20120.63 undefined
20110.29 undefined
20100.25 undefined
20090.23 undefined
20080.22 undefined
20070.19 undefined
20060.16 undefined
20050.15 undefined
20040.13 undefined

Fresenius SE & Co KGaA dividend payout ratio

In 2024, Fresenius SE & Co KGaA had a payout ratio of 31.8%. The payout ratio indicates the percentage of the company's profits that Fresenius SE & Co KGaA distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Fresenius SE & Co KGaA represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Fresenius SE & Co KGaA could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Fresenius SE & Co KGaA's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Fresenius SE & Co KGaA Payout Ratio History

DateFresenius SE & Co KGaA Payout ratio
2030e27.94 %
2029e28.2 %
2028e27.25 %
2027e28.39 %
2026e28.97 %
2025e24.39 %
2024e31.8 %
202330.71 %
202210.66 %
202154.03 %
202027.45 %
201923.68 %
201820.62 %
201719.05 %
201619.39 %
201517.41 %
201421.2 %
201320.04 %
201235.78 %
201120.62 %
201020 %
200923.81 %
200820 %
200721.11 %
200623.16 %
200525.23 %
200430.3 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Fresenius SE & Co KGaA.

Fresenius SE & Co KGaA latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.71 0.69  (-3.48 %)2024 Q3
6/30/20240.74 0.81  (8.96 %)2024 Q2
3/31/20240.71 0.67  (-6.22 %)2024 Q1
12/31/20230.7 -1.09  (-255.05 %)2023 Q4
9/30/20230.63 -0.72  (-214.16 %)2023 Q3
6/30/20230.6 0.67  (12.21 %)2023 Q2
3/31/20230.6 0.61  (1.79 %)2023 Q1
12/31/20220.9 0.27  (-70.09 %)2022 Q4
9/30/20220.71 0.66  (-6.91 %)2022 Q3
6/30/20220.83 0.68  (-18.4 %)2022 Q2
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Fresenius SE & Co KGaA stock

Eulerpool World ESG Rating (EESG©)

88/ 100

🌱 Environment

96

👫 Social

99

🏛️ Governance

69

Environment

Scope 1 - Direct Emissions
563,000
Scope 2 - Indirect emissions from purchased energy
899,000
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
1,462,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees69
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fresenius SE & Co KGaA shareholders

%
Name
Stocks
Change
Date
26.95876 % Else Kroner-Fresenius Foundation151,842,50902/6/2024
4.48468 % BlackRock Institutional Trust Company, N.A.25,259,504-1,133,57510/1/2024
2.99178 % Harris Associates L.P.16,850,886-160,8458/20/2024
2.94642 % Allianz Global Investors GmbH16,595,436011/6/2023
2.44480 % Amundi Asset Management, SAS13,770,083011/6/2023
2.24897 % The Vanguard Group, Inc.12,667,113-37,1659/30/2024
1.64381 % DWS Investment GmbH9,258,61211,0809/30/2024
1.51831 % Norges Bank Investment Management (NBIM)8,551,711-1,967,0176/30/2024
1.26801 % Fidelity Management & Research Company LLC7,141,9241,117,3958/31/2024
1.12882 % Franklin Mutual Advisers, LLC6,357,950-73,6919/30/2024
1
2
3
4
5
...
10

Fresenius SE & Co KGaA Executives and Management Board

Mr. Michael Sen

(55)
Fresenius SE & Co KGaA Chairman of the Management Board
Compensation 2.56 M

Dr. Sebastian Biedenkopf

(58)
Fresenius SE & Co KGaA Member of the Management Board, Responsible for Human Resources, Labor Relations Director, Risk Management and Legal
Compensation 1.53 M

Dr. Ernst Wastler

(65)
Fresenius SE & Co KGaA Member of the Management Board, Chief Executive Officer of Business Segment Fresenius Vamed
Compensation 1.27 M

Ms. Sara Hennicken

(43)
Fresenius SE & Co KGaA Chief Financial Officer, Member of the Management Board
Compensation 427,000

Dr. Dieter Schenk

(71)
Fresenius SE & Co KGaA Deputy Chairman of the Supervisory Board
Compensation 385,000
1
2
3
4
...
5

Fresenius SE & Co KGaA Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Formosa Laboratories Stock
Formosa Laboratories
SupplierCustomer0,870,600,340,220,750,54
DaVita Stock
DaVita
SupplierCustomer0,840,710,060,150,700,29
Austar Lifesciences Stock
Austar Lifesciences
SupplierCustomer0,780,690,480,330,650,43
SAP Stock
SAP
SupplierCustomer0,750,43-0,210,530,700,56
Paragon ID Stock
Paragon ID
SupplierCustomer0,720,390,230,570,530,31
Fresenius Medical Care Stock
Fresenius Medical Care
SupplierCustomer0,690,620,700,300,840,59
Soho Global Health Stock
Soho Global Health
SupplierCustomer0,630,52-0,440,240,610,33
Xi'An Global Printing A Stock
Xi'An Global Printing A
SupplierCustomer0,510,02-0,52-0,040,600,38
AbbVie Stock
AbbVie
SupplierCustomer0,350,400,73-0,33-0,69-0,38
Kendrion Stock
Kendrion
SupplierCustomer0,330,25-0,120,560,810,22
1
2

Most common questions regarding Fresenius SE & Co KGaA

What values and corporate philosophy does Fresenius SE & Co KGaA represent?

Fresenius SE represents values of innovation, quality, and patient care in its corporate philosophy. As a leading healthcare company, Fresenius SE is committed to providing high-quality products and services for patients worldwide. It focuses on four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. These divisions serve different aspects of healthcare, such as dialysis, infusion therapy, hospital operations, and project development. With a strong emphasis on research and development, Fresenius SE constantly strives to improve medical treatments and enhance patient well-being. By upholding these values, Fresenius SE has become a trusted name in the healthcare industry.

In which countries and regions is Fresenius SE & Co KGaA primarily present?

Fresenius SE is primarily present in numerous countries and regions around the world. The company operates in various key markets, including Germany, North America, Europe, Latin America, Asia-Pacific, and Africa. With a global presence, Fresenius SE has established a strong foothold in these regions, allowing it to expand its reach and serve a diverse customer base. The company's commitment to delivering high-quality healthcare products and services has enabled it to successfully operate and thrive in these international markets.

What significant milestones has the company Fresenius SE & Co KGaA achieved?

Fresenius SE, a leading healthcare company, has achieved several significant milestones throughout its history. It successfully expanded its global presence, delivering high-quality healthcare products and services to millions of patients worldwide. Fresenius SE also made notable advancements in the field of dialysis, offering innovative solutions for the treatment of chronic kidney failure. Moreover, the company has been at the forefront of pharmaceutical manufacturing and distribution, ensuring the availability of essential medications for various medical conditions. With a strong dedication to patient care and continuous innovation, Fresenius SE has consistently enhanced the quality of life for individuals around the globe.

What is the history and background of the company Fresenius SE & Co KGaA?

Fresenius SE is a prominent healthcare company with a rich history and background. Founded in 1912 by Dr. Eduard Fresenius, the company started as a pharmaceutical laboratory in Germany. Over the years, it expanded its services and is now a global leader in dialysis products, hospital equipment, and healthcare services. With a strong commitment to improve the quality of life for patients worldwide, Fresenius SE operates through its four business segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Its innovative technologies, extensive expertise, and global presence have propelled Fresenius SE to become a trusted name in the healthcare industry.

Who are the main competitors of Fresenius SE & Co KGaA in the market?

The main competitors of Fresenius SE in the market include Baxter International Inc, DaVita Inc, and Cardinal Health Inc.

In which industries is Fresenius SE & Co KGaA primarily active?

Fresenius SE is primarily active in the healthcare industry.

What is the business model of Fresenius SE & Co KGaA?

Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.

What is the P/E ratio of Fresenius SE & Co KGaA 2025?

The Fresenius SE & Co KGaA P/E ratio is 11.

What is the P/S ratio of Fresenius SE & Co KGaA 2025?

The Fresenius SE & Co KGaA P/S ratio is 0.91.

What is the Quality Investing of Fresenius SE & Co KGaA?

The Quality Investing for Fresenius SE & Co KGaA is 2/10.

What is the revenue of Fresenius SE & Co KGaA 2025?

The expected Fresenius SE & Co KGaA revenue is 22.94 B EUR.

How high is the profit of Fresenius SE & Co KGaA 2025?

The expected Fresenius SE & Co KGaA profit is 1.9 B EUR.

What is the business model of Fresenius SE & Co KGaA

Fresenius SE is a globally leading healthcare company based in Germany. The company consists of four main business segments, including Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care is the world's largest provider of dialysis products and services. Their portfolio includes dialysis machines, dialysis filters, and accessories, as well as innovative therapies such as hemodiafiltration and online hemodiafiltration. Additionally, Fresenius Medical Care offers comprehensive services for patients with chronic kidney diseases, including consultation, training, and support for better quality of life. Fresenius Kabi manufactures products for infusion and nutrition therapy and is a global market leader in this field. Their portfolio includes parenteral nutrition products, infusion solutions, pain therapeutics, and antibiotics. Furthermore, Fresenius Kabi provides intensified therapeutic care for patients to enable a quick recovery. Fresenius Helios is Europe's largest private hospital operator. The company operates over 100 acute clinics, rehabilitation clinics, and outpatient clinics in Germany and Spain, with a total of more than 100,000 beds. Fresenius Helios offers a wide range of medical services, including emergency care, oncology and neurology, cardiology, and orthopedics. Fresenius Vamed is an internationally active service provider for healthcare and social infrastructure. The company offers planning, construction, management, and optimization of healthcare facilities, as well as energy-efficient solutions for facility management. Fresenius Vamed also operates rehabilitation facilities, wellness facilities, and obesity centers. Fresenius SE was founded in 1912 and currently employs over 300,000 employees in over 100 countries. The company is headquartered in Bad Homburg vor der Höhe, Germany, and is listed on the Frankfurt Stock Exchange. Overall, Fresenius SE offers a wide range of products and services for all areas of healthcare, from dialysis and infusion therapy to hospital care and health infrastructure. The company is committed to improving the quality of life of their patients and ensuring high-quality medical care.

What is the Fresenius SE & Co KGaA dividend?

Fresenius SE & Co KGaA pays a dividend of 0.66 EUR distributed over 1 payouts per year.

How often does Fresenius SE & Co KGaA pay dividends?

Fresenius SE & Co KGaA pays out a dividend 1 times a year.

What is the Fresenius SE & Co KGaA ISIN?

The ISIN of Fresenius SE & Co KGaA is DE0005785604.

What is the Fresenius SE & Co KGaA WKN?

The WKN of Fresenius SE & Co KGaA is 578560.

What is the Fresenius SE & Co KGaA ticker?

The ticker of Fresenius SE & Co KGaA is FRE.DE.

How much dividend does Fresenius SE & Co KGaA pay?

Over the past 12 months, Fresenius SE & Co KGaA paid a dividend of 0.92 EUR . This corresponds to a dividend yield of about 2.48 %. For the coming 12 months, Fresenius SE & Co KGaA is expected to pay a dividend of 0.96 EUR.

What is the dividend yield of Fresenius SE & Co KGaA?

The current dividend yield of Fresenius SE & Co KGaA is 2.48 %.

When does Fresenius SE & Co KGaA pay dividends?

Fresenius SE & Co KGaA pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Fresenius SE & Co KGaA?

Fresenius SE & Co KGaA paid dividends every year for the past 0 years.

What is the dividend of Fresenius SE & Co KGaA?

For the upcoming 12 months, dividends amounting to 0.96 EUR are expected. This corresponds to a dividend yield of 2.59 %.

In which sector is Fresenius SE & Co KGaA located?

Fresenius SE & Co KGaA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fresenius SE & Co KGaA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fresenius SE & Co KGaA from 5/22/2023 amounting to 0.92 EUR, you needed to have the stock in your portfolio before the ex-date on 5/18/2023.

When did Fresenius SE & Co KGaA pay the last dividend?

The last dividend was paid out on 5/22/2023.

What was the dividend of Fresenius SE & Co KGaA in the year 2024?

In the year 2024, Fresenius SE & Co KGaA distributed 0.92 EUR as dividends.

In which currency does Fresenius SE & Co KGaA pay out the dividend?

The dividends of Fresenius SE & Co KGaA are distributed in EUR.

All fundamentals about Fresenius SE & Co KGaA

Our stock analysis for Fresenius SE & Co KGaA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius SE & Co KGaA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.